Occurrence of neuronal inclusions combined with increased nigral expression of α-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice

Brain Research Bulletin

Volumn 65, Issue 5, 2005, Pages 405-413

  Fornai, Francesco ^a,b   Lenzi, Paola ^a   Ferrucci, Michela ^a   Lazzeri, Gloria ^a   Di Poggio, Adolfo Bandettini ^a   Natale, Gianfranco ^a   Busceti, Carla L ^b   Biagioni, Francesca ^b   Giusiani, Mario ^a   Ruggieri, Stefano ^b,c   Paparelli, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Ecstasy; Methamphetamine; Methylenedioxymethamphetamine; Parkinson's disease; Substantia nigra

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALPHA SYNUCLEIN; METHAMPHETAMINE;

ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; DENERVATION; DOPAMINERGIC NERVE CELL; DRUG ABUSE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

EID: 20144389039     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2005.02.022     Document Type: Article

References (41)

1. D.S. Albers, and P.K. Sonsalla Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents J. Pharmacol. Exp. Ther. 275 1995 1104 1114
2. S.F. Ali, G.D. Newport, and W. Slikker Jr. Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents Ann. N. Y. Acad. Sci. 801 1996 187 198
3. J.F. Bowyer, A.W. Tank, G.D. Newport, W. Slikker Jr., S.F. Ali, and R.R. Holson The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum J. Pharmacol. Exp. Ther. 260 1992 817 824
4. V. Charles, E. Mezey, P.H. Reddy, A. Dehejia, T.A. Young, M.H. Polymeropoulos, M.J. Brownstein, and D.A. Tagle Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models Neurosci. Lett. 289 2000 29 32
5. K.A. Conway, J.C. Rochet, R.M. Bieganski, and P.T. Lansbury Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346 1349
6. K.K. Dev, K. Hofele, S. Barbieri, V.L. Buchman, and H. Van der Putten Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease Neuropharmacology 45 2003 14 44
7. M. Farrer, J. Kachergus, L. Forno, S. Lincoln, D.S. Wang, M. Hulihan, D. Maragonore, K. Gwinn-Hardy, Z. Wszolek, D. Dickson, and J.W. Langston Comparison of kindreds with parkinsonism and a-synuclein genomic multiplications Ann. Neurol. 55 2004 174 179
8. M.B. Feany, and W.W. Bender A Drosophila model of Parkinson's disease Nature 404 2000 394 398
9. F. Fornai, M. Gesi, M. Saviozzi, P. Lenzi, S. Piaggi, M. Ferrucci, and A. Casini Immunohistochemical evidence and ultrastructural compartmentalization of a new antioxidant enzyme in the rat substantia nigra J. Neurocytol. 30 2001 97 105
10. F. Fornai, F.S. Giorgi, M. Gesi, K. Chen, M.G. Alessandrì, and J.C. Shih Biochemical effects of monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B deficient mice Synapse 39 2001 213 221
11. F. Fornai, P. Lenzi, G. Frenzilli, M. Gesi, M. Ferrucci, G. Lazzeri, F. Biagioni, M. Nigro, A. Falleni, M. Giusiani, A. Pellegrini, F. Blandini, S. Ruggieri, and A. Paparelli DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy) Psychopharmacology 173 2004 353 363
12. F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C.L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M.G. Alessandrì, and A. Paparelli Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death following proteasome inhibitors J. Neurosci. 23 2003 8955 8966
13. F. Fornai, P. Lenzi, M. Gesi, P. Soldani, M. Ferrucci, G. Lazzeri, L. Capobianco, G. Battaglia, A. De Blasi, F. Nicoletti, and A. Paparelli Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells J. Neurochem. 88 2004 114 123
14. F. Fornai, S. Piaggi, M. Gesi, M. Saviozzi, P. Lenzi, A. Paparelli, and A.F. Casini Subcellular localization of a glutathione-dependent dehydroascorbate reductase within specific rat brain region Neuroscience 104 2001 15 31
15. K.B.J. Franklin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 1997 Academic Press London
16. W.P. Gai, D.L. Pountny, J.H. Power, Q.X. Li, J.G. Culvenor, C.A. McLean, P.H. Jensen, and P.C. Blumbergs Alpha-synuclein fibrils constitute the central core of oligodendroglial inclusions filaments in multiple system atrophy Exp. Neurol. 181 2003 68 78
17. O. Hornykiewicz Dopamine and Parkinson's disease. A personal view of the past, the present, and the future Adv. Neurol. 86 2001 1 11
18. K.A. Jellinger Neuropathological spectrum of synucleinopathies Mov. Disord. 18 2003 S2 S12
19. J.M. Jenco, A. Rawlingston, B. Daniels, and A.J. Morris Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins Biochemistry 37 1998 4901 4909
20. D. Kirik, L.E. Annett, C. Burger, N. Muzyczka, R.J. Mandel, and A. Björklund Nigrostriatal a-synucleinopathy induced by viral vector-mediated overexpression of human a-synuclein: a new primate model of Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 100 2003 2884 2889
21. D. Kirik, C. Rosenblad, C. Burger, C. Lundberg, T.E. Johansen, N. Muzyczka, R.J. Mandel, and A. Björklund Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system J. Neurosci. 22 2002 2780 2791
22. M.S. Kleven, and L.S. Seiden Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum Brain Res. 557 1991 340 343
23. R. Kruger, W. Kuhn, T. Mueller, D. Woitalla, M. Graeber, S. Kosel, H. Przuntek, J.T. Epplen, L. Schols, and O. Riess Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease Nat. Genet. 18 1998 106 108
24. F.H. Lewy M. Lewandowsky Handbuch der Neurologie 1912 Springer Berlin pp. 920-933
25. C. Lo Bianco, J.L. Ridet, B.L. Schneider, N. Deglon, and P. Aebischer A-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's desease Proc. Natl. Acad. Sci. U.S.A. 99 2002 10813 10818
26. J. Lotharius, and P. Brundin Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease Hum. Mol. Gen. 11 2002 2395 2407
27. L. Maroteaux, and R.H. Scheller The rat brain synucleins; family of proteins transiently associated with neuronal membrane Brain Res. Mol. Brain Res. 11 1999 335 343
28. D.C. Mash, Q. Ouyang, J. Pablo, M. Basile, S. Izenwasser, A. Lieberman, and R.J. Perrin Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons J. Neurosci. 23 2003 2564 2571
29. E. Masliah, E. Rockenstain, I. Veinbergs, M. Mallory, M. Hashimoto, A. Takeda, Y. Sagara, A. Sisk, and L. Mucke Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders Science 287 2000 1265 1269
30. D.B. Miller, and J.P. O'Callaghan Environment-drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse J. Pharmacol. Exp. Ther. 270 1994 752 760
31. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.J. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. Di Iorio, L.I. Golbe, and R.L. Nusshbaum Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
32. A. Recchia, P. Debetto, A. Negro, D. Guidolin, S.D. Skaper, and P. Giusti α-Synuclein and Parkinson's disease FASEB J. 18 2004 617 626
33. R.B. Rothman, S. Jayanthi, X. Wang, C.M. Dersch, J.L. Cadet, T. Prisinzano, K.C. Rice, and M.H. Baumann High-dose flenfuramiine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain Synapse 50 2003 233 239
34. O.M. Schluter, F. Fornai, M.G. Alessandrì, S. Takamori, M. Geppert, R. Jahn, and T.C. Sudhof Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice Neuroscience 118 2003 985 1002
35. A. Sidhu, C. Wersinger, and P. Vernier α-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease FEBS Lett. 565 2004 1 5
36. A. Sidhu, C. Wersinger, and P. Vernier Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 18 2004 637 647
37. A.B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M.R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy Alpha-synuclein locus triplication causes Parkinson's disease Science 302 2003 841
38. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert α-Synuclein in Lewy bodies Nature 388 1997 839 840
39. D. Sulzer Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation Nat. Med. 7 2001 1280 1282
40. D. Sulzer, N.T. Maidment, and S. Rayport Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons J. Neurochem. 60 1993 527 535
41. A. Takeda, M. Mallory, M. Sundsmo, W. Honer, L. Hansen, and E. Masliah Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders Am. J. Pathol. 152 1998 367 372